CELL BIOTECH

Probiotics & Microbiome company

2022 Earnings Release

2023. 02. 17.

1

As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to the external audit process, and may cause the actual results to differ from those stated or implied in this material.

Revenue up 7.8% to KRW 50.5 billion, operating profit down 14% to KRW 6.3 billion

Domestic revenue down 5.5%, overseas revenue up 30.7%

Duolac brand sales up 0.7% to KRW 29.6 billion, OEM/ODM sales up 40% to KRW 15.5 billion, Raw material sales down 15.5% to KRW 5.4 billion

(unit : KRW 100 mil)

	2021	% of revenue	2022	% of revenue	YoY(%)
Revenue	468.8		505.3		7.8
Domestic	297.0	63.4	280.7	55.6	-5.5
Overseas	171.7	36.6	224.5	44.4	30.7
	2021	Profit margin (%)	2022	Profit margin (%)	YoY(%)
Operating Profit	72.6	15.5	62.7	12.4	-13.6
Net Profit	103.8	22.1	96.8	19.2	-6.8

Revenue up 14.7% to KRW 13.8 billion, operating profit down 25.6% to KRW 1.7 billion

Domestic revenue up 2.1%, overseas revenue up 33.6%

Duolac brand sales up 6.7% to KRW 7.73 billion, OEM/ODM sales up 68.6% to KRW 4.9 billion, Raw material sales down 37.2% to KRW 1.2 billion


(unit : KRW 100 mil)

	2021 4q	% of revenue	2022 4q	% of revenue	YoY(%)
Revenue	120.3		138.1		14.7
Domestic	72.3	60.0	73.8	53.4	2.1
Overseas	48.1	40.0	64.3	46.6	33.6
	2021 4q	Profit margin (%)	2022 4q	Profit margin (%)	YoY(%)
Operating Profit	22.8	19.0	17.0	12.3	-25.6
Net Profit	29.3	24.4	-20.3	-14.7	Turn Red


Revenue trends

CELL BIOTECH

4q revenue KRW 13.8 billion, yoy +14.7% Domestic sales up 2.1%, Overseas sales up 33.6% Duolac +6.7%, OEM/ODM +68.6%, and raw material -37.2%



Full year revenue KRW 50.5 billion, yoy +7.8% Domestic sales down 5.5%, Overseas sales up 30.7% Duolac +0.7%, OEM/ODM +40.0%, and raw material -15.5%




Profit trends

CELL BIOTECH


4q operating profit KRW 1.7 billion, yoy -25.6% Net non operating profit KRW +4.3 bil. (net interest income +0.5 bil.) Net Profit KRW -2.03 bil.



Full year op. profit KRW 6.3 billion, yoy -13.6% Net non operating profit KRW +5.5 bil. (net interest income +2.2 bil.) Net Profit KRW 9.7 bil.



4q revenue of Duolac brand +6.7% to KRW 7.7 bil., OEM/ODM +68.6% to KRW 4.9 bil., and raw material -37.2% to KRW 1.2 bil. revenue increase in Europe +58% and Asia +5%



CELL BIOTECH

Business update

CELL BIOTECH

Microbiome R&D

1) Microbiome First-in-Class anticancer pipeline 'PP-P8'

clinical phase 1 IND submitted (Mar 5, 2021)



- 2) Acquisition European patent of PP-P8 (Apr 1, 2021) (patent number EP3453718)
- 3) Acquired US patent for Probiotics drug delivery system(22, 12, 20)

4) GMP facilities for LBP completed due diligence (1H 2021)

Microbiome business activity

1) The 43th Probiotics seminar for pharmacist (Oct 20~22, 2022)



New Brand – DUOLAB



- Launched nutritional supplement brand DUOLAB (22.11.15)
- Improved nutrient absorption rate with probiotic technology

Consolidated Financial Summary

Income statement			(unit : KRW 100 mil., %)	
	2021		2022	
	Amount	Ratio	Amount	Ratio
Revenue	468.7	100.0	505.3	100.0
Gross profit	356.8	76.1	382.4	75.7
SG&A expenses	284.3	60.6	319.7	63.3
Operating profit	72.6	15.5	62.7	12.4
Non operating profit/expense	48.3	10.3	55.2	10.9
Profit before tax	120.9	25.8	117.9	23.3
Consolidated net income	103.8	22.2	96.8	19.2

Statement of financial position

(unit : KRW 100 mil., %)

	2021. 12	2022. 12
Assets	1,129	1,168
Current Assets	675	761
Non current Assets	454	407
Liabilities	62	87
Current Liabilities	58	83
Non current Liabilities	4	4
Shareholder's Equity	1,067	1,081
Capital Stock	47	47
Retained Earnings	1,099	1,164

CELL BIOTECH